Research graph
References from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
The global burden of urinary bladder cancer: an update
10.1007/s00345-019-02984-4 · 2020 · External reference
Epidemiology and risk factors of urothelial bladder cancer
10.1016/j.eururo.2012.07.033 · 2013 · External reference
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
10.1200/jco.2001.19.3.666 · 2001 · External reference
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
10.1056/nejmoa022148 · 2003 · External reference
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
10.1200/jco.2000.18.17.3068 · 2000 · External reference
Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer
10.1056/nejmoa2408154 · 2024 · External reference
Perioperative enfortumab vedotin and pembrolizumab in bladder cancer
10.1056/nejmoa2511674 · 2026 · External reference
A consensus molecular classification of muscle-invasive bladder cancer
10.1016/j.eururo.2019.09.006 · 2020 · External reference
Comprehensive molecular characterization of urothelial bladder carcinoma
10.1038/nature12965 · 2014 · External reference
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
10.1016/j.ccell.2024.10.016 · 2024 · External reference
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024 · External reference
Intrinsic subtypes and bladder cancer metastasis
10.1016/j.ajur.2016.09.009 · 2016 · External reference
The origin and evolution of bladder cancer stem cells
10.3389/fcell.2022.950241 · 2022 · External reference
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
10.1016/j.ccr.2014.01.009 · 2014 · External reference
Comprehensive molecular characterization of muscle-invasive bladder cancer
10.1016/j.cell.2017.09.007 · 2017 · External reference
Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer
10.1007/s10555-015-9589-6 · 2015 · External reference
Cancer cell plasticity during tumor progression, metastasis and response to therapy
10.1038/s43018-023-00595-y · 2023 · External reference
Tumor heterogeneity and consequences for bladder cancer treatment
10.3390/cancers13215297 · 2021 · External reference
Mechanisms and implications of epithelial cell plasticity in the bladder
10.1038/s41585-025-01066-y · 2026 · External reference
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers
10.1038/s41467-020-16162-3 · 2020 · External reference
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
10.1038/s41467-022-34251-3 · 2022 · External reference
Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer
10.1073/pnas.2008017117 · 2020 · External reference
Spatial omics and multiplexed imaging to explore cancer biology
10.1038/s41592-021-01203-6 · 2021 · External reference
Exploring tissue architecture using spatial transcriptomics
10.1038/s41586-021-03634-9 · 2021 · External reference
Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics
10.1038/s41576-021-00370-8 · 2021 · External reference
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis
10.1016/j.ccell.2025.02.009 · 2025 · External reference
Spatial cellular architecture predicts prognosis in glioblastoma
10.1038/s41467-023-39933-0 · 2023 · External reference
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
10.1038/s41588-024-01998-y · 2025 · External reference
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer
10.1016/j.ccell.2025.01.012 · 2025 · External reference
Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial–fibroblast interactions in recurrent bladder cancer
10.1002/ctm2.1338 · 2023 · External reference
The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
10.1186/s12967-023-04151-1 · 2023 · External reference
Single-nucleus and spatially resolved intratumor subtype heterogeneity in bladder cancer
10.1016/j.euros.2023.03.006 · 2023 · External reference
Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma
10.1038/s42003-023-05668-3 · 2023 · External reference
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer
10.1038/s41467-021-25103-7 · 2021 · External reference
Robust decomposition of cell type mixtures in spatial transcriptomics
10.1038/s41587-021-00830-w · 2022 · External reference
Spatially resolved clonal copy number alterations in benign and malignant tissue
10.1038/s41586-022-05023-2 · 2022 · External reference
Single-cell transcriptional diversity is a hallmark of developmental potential
10.1126/science.aax0249 · 2020 · External reference
The single-cell transcriptional landscape of mammalian organogenesis
10.1038/s41586-019-0969-x · 2019 · External reference
Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours
10.1007/s10549-012-2024-6 · 2012 · External reference
High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma
10.1016/j.humpath.2023.11.002 · 2023 · External reference
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
10.1073/pnas.1318376111 · 2014 · External reference
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
10.1186/s13045-022-01349-6 · 2022 · External reference
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
10.1038/s41392-023-01705-z · 2023 · External reference
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
10.1038/nrclinonc.2018.8 · 2018 · External reference
Single-cell and spatial mapping identify cell types and signaling networks in the human ureter
10.1016/j.devcel.2022.07.004 · 2022 · External reference
FOXA1, GATA3 and PPARɣ cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines
10.1038/srep38531 · 2016 · External reference
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
10.1038/s41467-018-06081-9 · 2018 · External reference
Tertiary lymphoid structures in anticancer immunity
10.1038/s41568-024-00728-0 · 2024 · External reference
Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer
10.1038/s41416-024-02917-y · 2025 · External reference
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer
10.1002/cac2.12447 · 2023 · External reference
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
10.1038/s41698-024-00533-w · 2024 · External reference
Mature tertiary lymphoid structures indicate good chemotherapy response and prognosis in advanced colorectal cancer
10.1002/ags3.70142 · 2025 · External reference
Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma
10.1158/0008-5472.can-17-1987 · 2018 · External reference
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
10.1080/2162402x.2017.1378844 · 2018 · External reference
Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity
10.1038/mt.2015.120 · 2015 · External reference
Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas
10.1136/gutjnl-2022-328697 · 2023 · External reference
Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade
10.1158/2326-6066.cir-21-0515 · 2022 · External reference
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
10.1038/s41591-023-02371-y · 2023 · External reference
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis
10.1002/art.22939 · 2007 · External reference
IL-17–induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs
10.1084/jem.20131737 · 2014 · External reference
CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer
10.1016/j.ejca.2021.03.054 · 2021 · External reference
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy
10.1016/j.ctrv.2017.11.007 · 2018 · External reference
MIF-dependent control of tumor immunity
10.3389/fimmu.2020.609948 · 2020 · External reference
NAMPT-driven M2 polarization of tumor-associated macrophages leads to an immunosuppressive microenvironment in colorectal cancer
10.1002/advs.202303177 · 2024 · External reference
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
10.1038/s41591-019-0628-7 · 2019 · External reference
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study
10.1200/jco.18.01148 · 2018 · External reference
Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models
10.1158/0008-5472.can-15-1313 · 2016 · External reference
Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin
10.1158/1078-0432.ccr-20-4175 · 2021 · External reference
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study
10.1093/oncolo/oyaf342 · 2025 · External reference
